Amplifica
Private Company
Total funding raised: $15M
Overview
Amplifica is a private, clinical-stage biotech founded in 2019, targeting the multi-billion dollar hair loss market. The company's core technology involves unique signaling molecules to stimulate hair follicles, with its lead candidate, AMP-303, having generated positive first-in-human clinical data. Led by a team with a strong track record in aesthetics and biopharma, including prior successful exits, Amplifica is advancing a pipeline of four next-generation programs and is positioned to capitalize on a significant unmet medical need.
Technology Platform
Identification and isolation of unique signaling molecules that stimulate hair follicles to regrow hair, targeting multiple mechanisms of action.
Funding History
2Opportunities
Risk Factors
Competitive Landscape
Amplifica competes in the hair loss treatment market against approved drugs like minoxidil and finasteride, procedural treatments (transplants), and a growing pipeline of biotech candidates. Its differentiation hinges on the novel mechanism of its signaling molecules and the goal of achieving superior efficacy in regrowing hair. Large dermatology/aesthetics firms like AbbVie (Allergan) are dominant incumbents and potential acquirers.